Clostridioides difficile Infection in Children With Inflammatory Bowel Disease.

Clostridioides difficile Infection in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Nov 25;: Authors: Chandrakumar A, Zohni H, El-Matary W Abstract BACKGROUND: The study’s objective was to investigate the incidence and risk factors associated with Clostridioides difficile (previously known as Clostridium) infection (CDI) in children with inflammatory bowel disease (IBD) in the province of Manitoba. METHODS: Our longitudinal population-based cohort was comprised of all children and young adults aged <17 years diagnosed with IBD in the Canadian province of Manitoba between 2011 and 2019. The diagnosis of CDI…

Read More

A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice.

Related Articles A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Liso M, De Santis S, Verna G, Dicarlo M, Calasso M, Santino A, Gigante I, Eri R, Raveenthiraraj S, Sobolewski A, Palmitessa V, Lippolis A, Mastronardi M, Armentano R, Serino G, De Angelis M, Chieppa M Abstract BACKGROUND: Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a multifactorial disorder characterized by chronic inflammation and altered gut barrier function. Dysbiosis, a condition defined by dysregulation…

Read More

Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis.

Related Articles Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S Abstract BACKGROUND: Longer disease duration is associated with inferior response to biologic therapy in Crohn’s disease. However, the effect of disease duration on response to biologic therapy in ulcerative colitis (UC) has not been well studied. METHODS: In a single-center retrospective cohort study of outpatients with UC starting a biologic agent, we…

Read More

Response to the Letter to the Editor: “Response to Infliximab After Loss of Response to Adalimumab in Crohn’s Disease”.

Response to the Letter to the Editor: “Response to Infliximab After Loss of Response to Adalimumab in Crohn’s Disease”. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Casanova MJ, Chaparro M, Gisbert JP PMID: 31750908 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31750908?dopt=Abstract

Read More

Spontaneous Resolution of Enterocutaneous Fistula After Disseminated Tuberculosis Treatment in a Patient With Crohn’s Disease: Challenges in Biologic Therapy.

Spontaneous Resolution of Enterocutaneous Fistula After Disseminated Tuberculosis Treatment in a Patient With Crohn’s Disease: Challenges in Biologic Therapy. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Silva JC, Rodrigues A, Carvalho J PMID: 31750911 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31750911?dopt=Abstract

Read More

Alteration of Fungal Microbiota After 5-ASA Treatment in UC Patients.

Alteration of Fungal Microbiota After 5-ASA Treatment in UC Patients. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Jun X, Ning C, Yang S, Zhe W, Na W, Yifan Z, Xinhua R, Yulan L Abstract The effect of treatment regimens on fungal microbiota is unclear in ulcerative colitis (UC) patients. Here, we aimed to clarify the effect of 5-aminosalicylic acid (5-ASA) treatment on gut fungal microbiota in UC patients. Fifty-seven UC patients, including 20 treatment-naïve and 37 5-ASA-treated, were recruited into an exploration study. We compared the gut fungal profiles of…

Read More

Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients.

Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Basson AR, Gomez-Nguyen A, Menghini P, Buttó LF, Di Martino L, Aladyshkina N, Osme A, Lasalla A, Fischer D, Ezeji JC, Erkkila HL, Brennan CJ, Lam M, Rodriguez-Palacios A, Cominelli F Abstract BACKGROUND: Inflammatory bowel disease (IBD) is a lifelong digestive disease characterized by periods of severe inflammation and remission. To our knowledge, this is the first study showing a variable…

Read More

The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction.

The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. Inflamm Bowel Dis. 2019 Nov 21;: Authors: Sayoc-Becerra A, Krishnan M, Fan S, Jimenez J, Hernandez R, Gibson K, Preciado R, Butt G, McCole DF Abstract BACKGROUND: Alterations to epithelial tight junctions can compromise the ability of the epithelium to act as a barrier between luminal contents and the underlying tissues, thereby increasing intestinal permeability, an early critical event in inflammatory bowel disease (IBD). Tofacitinib (Xeljanz), an orally administered pan-Janus kinase (JAK) inhibitor, was recently approved…

Read More

Erratum: A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?

Erratum: A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping? Inflamm Bowel Dis. 2019 Nov 20;: Authors: Marcil V, Levy E, Amre D, Bitton A, Sant’Anna AMGA, Szilagy A, Sinnett D, Seidman EG PMID: 31746991 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31746991?dopt=Abstract

Read More
<< Go Back